1. 251 Type II but not type I interferon signifies clinical response to ustekinumab in patients with systemic lupus erythematosus. (April 2019) Authors: Jordan, Jarrat; Sweet, Kristen; Cesaroni, Matteo; Ma, Keying; Franks, Carol; Seridi, Loqmane; Schreiter, Jessica; Gordon, Robert; Lipsky, Peter; Vollenhoven, Ronald van; Tsokos, George C; Hahn, Bevra H; Rose, Shawn; Baribaud, Frédéric; Loza, Matthew J; Campbell, Kim Journal: Lupus science & medicine Issue: Volume 6(2019)supplement 1 Page Start: A185 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. Issue 2 (19th May 2021) Authors: Sweet, Kristen; Song, Qingxuan; Loza, Matthew J; McInnes, Iain B; Ma, Keying; Leander, Karen; Lakshminarayanan, Vani; Franks, Carol; Cooper, Philip; Siebert, Stefan Journal: RMD open Issue: Volume 7:Issue 2(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation. Issue 12 (6th September 2017) Authors: Silkoff, Philip E; Singh, Dave; FitzGerald, J Mark; Eich, Andreas; Ludwig-Sengpiel, Andrea; Chupp, Geoffrey C; Backer, Vibeke; Porsbjerg, Celeste; Girodet, Pierre-Olivier; Dransfield, Mark T; Baribaud, Frederic; Susulic, Vedrana S; Loza, Matthew J Journal: Biomarker insights Issue: Volume 2017:Issue 12(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP0118 DISCRETE PATTERNS OF CITRULLINATED PEPTIDE AUTOANTIBODY REACTIVITIES EMERGE DURING PROGRESSION FROM PRE-DISEASE STATE TO DIAGNOSIS OF RHEUMATOID ARTHRITIS. (June 2019) Authors: Loza, Matthew J; Nagpal, Sunil; Laird, Renee; Cole, Suzanne; Baribaud, Frederic; Anderson, Ian; Rao, Navin; Riddle, Mark; Porter, Chad Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP0278 BIOMARKER PROFILING REVEALS NOVEL MECHANISTIC INSIGHTS INTO USTEKINUMAB THERAPEUTIC RESPONSES IN SYSTEMIC LUPUS ERYTHEMATOSUS. (June 2019) Authors: Cesaroni, Matteo; Seridi, Loqmane; Jordan, Jarrat; Sweet, Kristen; Keying, MA; Franks, Carol; Schreiter, Jessica; Lipsky, Peter; Vollenhoven, Ronald van; Hahn, Bevra H.; Rose, Shawn; Baribaud, Frederic; Loza, Matthew J; Campbell, Kim; Tsokos, George Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 220 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P273 Ustekinumab and guselkumab treatment results in differences in serum IL-17A, IL-17F and CRP levels in PsA patients: a comparison from ustekinumab Phase 3 and guselkumab Phase 2 programmes. (20th April 2020) Authors: Siebert, Stefan; Loza, Matthew J; Song, Qingxuan; Gorecki, Patricia C; McInnes, Iain B; Sweet, Kristen Journal: Rheumatology Issue: Volume 59(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial. Issue 10 (24th April 2019) Authors: Sweet, Kristen; Dasgupta, Bidisha; de Vries, Dick; Gourley, Ian; Hsu, Benjamin; Loza, Matthew J; Taylor, Peter C Journal: Annals of the rheumatic diseases Issue: Volume 78:Issue 10(2019) Page Start: 1439 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial. Issue 10 (October 2019) Authors: Sweet, Kristen; Dasgupta, Bidisha; de Vries, Dick; Gourley, Ian; Hsu, Benjamin; Loza, Matthew J; Taylor, Peter C Journal: Annals of the rheumatic diseases Issue: Volume 78:Issue 10(2019) Page Start: 1439 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Issue 1 (15th May 2017) Authors: Brunner, Hermine I; Ruperto, Nicolino; Tzaribachev, Nikolay; Horneff, Gerd; Chasnyk, Vyacheslav G; Panaviene, Violeta; Abud-Mendoza, Carlos; Reiff, Andreas; Alexeeva, Ekaterina; Rubio-Pérez, Nadina; Keltsev, Vladimir; Kingsbury, Daniel J; del Rocio Maldonado Velázquez, Maria; Nikishina, Irina; Si... Journal: Annals of the rheumatic diseases Issue: Volume 77:Issue 1(2018) Page Start: 21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. THU0052 USTEKINUMAB AND GUSELKUMAB TREATMENT RESULTS IN DIFFERENCES IN SERUM IL17A, IL17F AND CRP LEVELS IN PSORIATIC ARTHRITIS PATIENTS: A COMPARISON FROM USTEKINUMAB PH3 AND GUSELKUMAB PH2 PROGRAMS. (June 2019) Authors: Siebert, Stefan; Loza, Matthew J; Song, Qingxuan; Mcinnes, Iain; Sweet, Kristen Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 293 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗